Paper Details

  1. Home
  2. Paper Details

[Efficacy and safety of intramuscular imipenem/cilastatin (IPM/CS) for complicated urinary tract infections].

Author: HashiguchiJ, HayashiM, HoriT, HoshinoK, IwasakiS, KiyokawaS, MaedaK, MarutaN, MatsuoR, MorimitsuH, NishimuraN, SaitoY, ShimomaeH, ShindoK, SuzuH, TaideM, YamadaJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Intramuscular administration of imipenem/cilastatin was effective in treating complicated urinary tract infections (UTIs) in a majority of patients. The efficacy rate was higher in patients with cystitis treated with a u.i.d. regimen compared to those with a b.i.d. regimen. The most common side effect was pain at the injection site, which was mild and transient.
Paper Details　
Original Abstract of the Article :
An intramuscular preparation of imipenem/cilastatin (IPM/CS, 500 mg/500 mg) was administered to 59 patients with complicated urinary tract infections (UTI; cystitis and pyelonephritis) to evaluate its efficacy and safety. The obtained results are summarized as follows: In patients with cystitis, eva...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/9743908

データ提供：米国国立医学図書館（NLM）

Imipenem/Cilastatin: A Powerful Tool for Battling Urinary Tract Infections

Urinary tract infections (UTIs), like a relentless desert wind, can cause significant discomfort and complications. This study, like a determined camel traversing harsh terrain, explores the efficacy and safety of imipenem/cilastatin (IPM/CS), an intramuscular antibiotic, for treating complicated UTIs. The researchers, through a meticulous clinical trial involving 59 patients, found that IPM/CS demonstrated a strong efficacy rate of 80% for treating both cystitis and pyelonephritis. The study also highlighted the microbiological eradication rate of 88%, with promising results against various bacterial strains, including Enterobacter faecalis and Pseudomonas aeruginosa.

A Desert Oasis of Antibiotic Efficacy

The study revealed a high efficacy rate of 80% for IPM/CS in treating complicated UTIs. This impressive result demonstrates the drug's potential for effectively combating both cystitis and pyelonephritis, offering a valuable weapon in the fight against these infections.

Navigating the Desert of UTIs: A Guide to Treatment and Prevention

This study offers a beacon of hope for individuals facing UTIs, highlighting the effectiveness of IPM/CS in treating these infections. However, it is crucial to remember that UTIs, like desert sands, can be tricky to navigate. Maintaining good hygiene and staying hydrated are vital in preventing UTIs.

Dr. Camel's Conclusion

This study, like a well-equipped camel traversing the desert, provides valuable insights into the treatment of complicated urinary tract infections. Imipenem/cilastatin demonstrates great potential as a potent antibiotic, offering a glimmer of hope in the face of these challenging infections.

Date :
  1. Date Completed 1998-12-11
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

9743908

DOI: Digital Object Identifier

9743908

SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.